Interventional Oncology Devices Market By Product (Embolization Devices, Ablation Devices, and Support Devices), By Procedure (Thermal Tumor Ablation, Non-Thermal Tumor Ablation, Transcatheter Arterial Chemoembolization, Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy, and Transcatheter Arterial Embolization/Bland Embolization), By Cancer (Liver Cancer, Lung Cancer, Bone Cancer, and Kidney Cancer), and By Region - Trends, Analysis and Forecast till 2030

Growing rates of cancer and its rising prevalence

The primary driver propelling the global interventional oncology device market is the rising incidence and prevalence of cancer among people worldwide. As to the WHO data released in 2018, cancer ranks as the second most common cause of death globally, with 9.6 million deaths attributable to it in 2018. About 70% of cancer-related deaths take place in low- and middle-income nations. Additionally, there is a strong preference for less invasive surgical techniques, favorable insurance policies in industrialized nations for interventional oncology treatments, access to both public and private funding, and other factors. Over the course of the forecast period, these factors are also anticipated to support the expansion of the global market. Nevertheless, the growing financial burden and dearth of clinical evidence for targeted region treatment The target market's growth is being hindered by industry participants who have a high number of product recalls. However, during the projected period, a rise in mergers and acquisitions among industry participants combined with new product releases is anticipated to generate profitable growth prospects for the target market.